Swiss Chems - Retatrutide Vial

Retatrutide is a 39-amino acid synthetic peptide engineered as a unimolecular triple receptor agonist, simultaneously activating the GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This SwissChems product provides Retatrutide in a single lyophilized vial for laboratory research.

Retatrutide is an investigational compound currently in Phase 3 clinical development. It is not approved by the FDA as a drug or dietary supplement. This product is intended strictly for research use and is not for human consumption. All information is for educational and research reference only.

Chemical Properties

Mechanism of Action

Retatrutide's triple agonism distinguishes it from the current generation of approved incretin-based therapies. GLP-1 receptor agonists (e.g., semaglutide) activate a single receptor; dual GLP-1/GIP agonists (e.g., tirzepatide) activate two. Retatrutide simultaneously activates all three, with particularly potent activity at the GIP receptor and attenuated but clinically meaningful activity at the GLP-1 and glucagon receptors.

Receptor-Level Actions

>

Enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite via central satiety signaling. >

Augments insulin secretion in a glucose-dependent manner and modulates adipose tissue metabolism; believed to contribute to improved tolerability relative to GLP-1–only agents. >

Activates hepatic glucagon signaling to increase energy expenditure, promote fatty acid oxidation, and reduce hepatic fat — the mechanism most notably absent from semaglutide and tirzepatide.

Structural Design

Retatrutide is engineered from the GIP peptide backbone, modified to achieve balanced activation across all three receptors. A C20 fatty diacid moiety enables albumin binding and extends the plasma half-life to approximately one week, consistent with once-weekly subcutaneous dosing in clinical protocols. Cryo-EM structural studies confirm distinct receptor-specific conformations at the extracellular loops of each receptor that explain how a single peptide achieves meaningful agonism at all three targets.

Phase 2 Clinical Research Summary

Retatrutide is one of the most clinically studied investigational peptides in the metabolic space. Two Phase 2 trials sponsored by Eli Lilly have been published in The New England Journal of Medicine and presented at major endocrinology conferences. The following findings are from those published trials and are cited for research reference only.

Obesity (without T2D)

>Placebo-adjusted weight reduction of

and

At the 12mg dose,>Average body weight reduction of

at 48 weeks in the 12mg cohort — the highest reported weight reduction for any pharmacological agent in a randomized trial at the time of publication >Reductions ≥5% body weight achieved in 100% of participants at the 8mg and 12mg doses >Phase 3 TRIUMPH-4 trial (obesity + knee osteoarthritis): average 28.7% body weight loss at 68 weeks with 12mg

Type 2 Diabetes

>HbA1c reductions of

vs. no change with placebo over ~24 weeks at 4–12mg doses >HbA1c below 6.5% achieved in up to 82% of participants at the 12mg dose >HbA1c below 5.7% (normoglycemia) in up to 31% of participants >Body weight loss approaching 17% at the 8mg and 12mg doses with no plateau at 36 weeks

NAFLD/NASH

>Hepatic steatosis resolved in over 85% of participants receiving 8mg and 12mg at 48 weeks.>Over 90% of participants with obesity and NAFLD achieved normalization of liver fat at the highest dose.>No hepatotoxicity signals were observed through 48 weeks

Safety Profile

Most common adverse events were gastrointestinal in nature (nausea, vomiting, diarrhea), occurring primarily during dose escalation — consistent with the safety profile seen across the GLP-1 agonist class. No novel safety signals beyond the GLP-1/GIP class were identified in Phase 2 trials.

Research Positioning vs. Approved Incretin Agents

Quality Assurance

SwissChems provides independent third-party Certificates of Analysis (COAs) for Retatrutide, verifying identity and purity through HPLC testing. The company guarantees product quality with a full refund policy that covers testing costs, the order value, and shipping if independent HPLC results do not match the label claims.

Research Dosing Reference

The following protocols are compiled from published Phase 2 clinical research for educational purposes only. This product is not for human consumption.

>

Subcutaneous injection in clinical trials >

Once weekly >

1mg, 4mg, 8mg, 12mg weekly (Phase 2 obesity trial) >

Gradual escalation from lower doses to minimize gastrointestinal side effects >

~7 days (once-weekly dosing supported by albumin-binding fatty acid moiety) >

Sterile bacteriostatic water; confirm concentration per research protocol

Regulatory Status

>

Investigational New Drug (IND). Phase 3 trials are ongoing. Not approved for human use. >

Eli Lilly and Company (LY3437943) >

Not explicitly listed; as a peptide hormone and metabolic modulator, likely subject to S2/S4 scrutiny — confirm current status before use in any tested context. >

Legal for research purchase when labeled "not for human consumption" in most jurisdictions.

Storage & Handling

>

-20°C freezer for long-term storage >

2–8°C refrigerator; use within 30 days >Avoid repeated freeze-thaw cycles >Protect from light and moisture at all times >Use sterile technique for all reconstitution and handling

Important Disclaimer

This product is intended strictly for laboratory research purposes. It is not intended for human consumption, therapeutic use, or self-administration. All clinical data cited is from published peer-reviewed research and is presented for educational purposes only — it does not constitute medical advice or a treatment recommendation.

Retatrutide is an investigational drug owned and developed by Eli Lilly and Company. SwissChems Retatrutide is a research-grade compound synthesized for non-clinical laboratory research. Researchers are responsible for understanding all applicable laws and institutional guidelines governing the purchase, storage, and use of their research materials.